تفاعل الدواء مع المستقبل: المضاد

Competitive antagonists bind reversibly to the same receptor site as agonists, competing for occupancy and reducing available receptors. Noncompetitive antagonists bind covalently to the active site, forming irreversible bonds that cannot be displaced by increasing agonist concentration. This fundamental difference determines whether an antagonist's effect can be overcome pharmacologically.

Increasing agonist concentration reverses the competitive antagonist's effect by restoring agonist-receptor binding. Because competitive antagonists compete for the same binding site, higher agonist concentrations can outcompete the antagonist and restore receptor activation. This reversibility distinguishes competitive antagonists from their noncompetitive counterparts.

Noncompetitive antagonists bind covalently and irreversibly to the receptor's active site, permanently blocking agonist access. Since the antagonist cannot be displaced regardless of agonist concentration, increasing agonist levels cannot restore binding. This irreversible mechanism results in reduced maximal efficacy of the agonist.

A competitive antagonist shifts the agonist's dose-response curve to the right, indicating that higher agonist concentrations are needed to produce the same response. This rightward shift reflects the reduced number of available receptors due to antagonist occupancy. Understanding this shift is central to dose response relationship potency and efficacy in pharmacology.

A noncompetitive antagonist lowers the maximal effect of an agonist by permanently occupying receptor sites through covalent binding. Even at high agonist concentrations, the irreversibly bound antagonist prevents activation of those receptors, reducing overall agonist efficacy. This results in a lower ceiling response compared to the agonist alone.

An antagonist binds strongly to a receptor without activating it, blocking access for agonists or endogenous ligands. By occupying the binding site or stabilizing the receptor's inactive state, the antagonist prevents the receptor from triggering its normal cellular response. This competitive or noncompetitive blockade effectively hinders physiological processes mediated by that receptor.

Naloxone and propranolol are competitive antagonists used to reverse opioid overdose and block heart receptors, respectively. Phenoxybenzamine and ketamine are noncompetitive antagonists that block alpha-adrenergic and NMDA receptors for various therapeutic purposes. The choice between competitive and noncompetitive antagonists depends on the desired clinical outcome and reversibility requirements.